CYTOGENETIC EVOLUTION FOLLOWING TRANSFORMATION OF MYELODYSPLASTIC SYNDROME (MDS) TO ACUTE MYELOGENOUS LEUKEMIA (AML)

被引：0
|
作者：
GHADDAR, H [1 ]
STASS, S [1 ]
CORK, A [1 ]
ESTEY, E [1 ]
机构：
[1] UNIV TEXAS,MD ANDERSON CANC CTR,HOUSTON,TX 77025
来源：
BLOOD | 1993年 / 82卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A376 / A376
页数：1
相关论文
共 50 条
  • [1] TRISOMY-14 IN ACUTE MYELOGENOUS LEUKEMIA (AML) AND MYELODYSPLASTIC SYNDROME (MDS)
    TOZE, CL
    BARNETT, MJ
    NAIMAN, SC
    HORSMAN, DE
    BLOOD, 1994, 84 (10) : A626 - A626
  • [2] CYTOGENETIC EVOLUTION FOLLOWING THE TRANSFORMATION OF MYELODYSPLASTIC-SYNDROME TO ACUTE MYELOGENOUS LEUKEMIA - IMPLICATIONS ON THE OVERLAP BETWEEN THE 2 DISEASES
    GHADDAR, HM
    STASS, SA
    PIERCE, S
    ESTEY, EH
    LEUKEMIA, 1994, 8 (10) : 1649 - 1653
  • [3] Acute myelogenous leukemia (AML) type induction chemotherapy for the patients with myelodysplastic syndrome (MDS)
    Kim, D.-Y.
    Kim, J.-S.
    Kim, B.-S.
    Bang, S.-M.
    Kim, I.
    Yoon, S.-S.
    Park, S.
    Kim, B. K.
    LEUKEMIA RESEARCH, 2007, 31 : S138 - S138
  • [4] Clonality of peripheral blood cells in acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS)
    Keyhani, A
    Gengenbacher, D
    SanchezWilliams, G
    Goodacre, A
    Andreeff, M
    BRITISH JOURNAL OF HAEMATOLOGY, 1996, 93 : 1347 - 1347
  • [5] Relationship of progression to acute myeloid leukemia (AML) from myelodysplastic syndrome (MDS) and cytogenetic status
    Hellstrom-Lindberg, E.
    Fenaux, P.
    Mufti, G. J.
    List, A. F.
    Santini, V.
    Gore, S.
    Seymour, J. F.
    Backstrom, J.
    McKenzie, D.
    Beach, C. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [6] Erythropoietin (EPO)-dependent transformation of myelodysplastic syndrome (MDS) to acute myeloid leukemia (AML).
    Bunworasate, U
    Arnouk, H
    Minderman, H
    O'Loughlin, KL
    Sait, SNJ
    Barcos, M
    Baer, MR
    BLOOD, 2000, 96 (11) : 259B - 259B
  • [7] Myelodysplastic Syndrome (MDS)-Associated Cytogenetic Abnormalities in Pediatric Chronic Myelogenous Leukemia
    Kumar, Kirthi R.
    Koduru, Prasad
    Timmons, Charles
    Monaghan, Sara
    Cavalier, MaryEllen
    Luu, Hung S.
    PEDIATRIC BLOOD & CANCER, 2013, 60 (11) : E146 - E148
  • [8] The pharmacokinetics of azacitidine following subcutaneous treatment in patients with myelodysplastic syndromes (MDS) or acute myelogenous leukemia (AML)
    Laille, E.
    Ward, R.
    Nasser, A.
    Stoltz, M.
    Cogle, C.
    Gore, S.
    Skikne, B. S.
    Garcia-Manero, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [9] Zevalin™ radioimmunotherapy is not associated with an increased incidence of secondary myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML).
    Czuczman, M
    Witzig, TE
    Gaston, I
    Skikne, BS
    Dimitrov, G
    Gordon, LI
    Emmanouilides, C
    White, CA
    BLOOD, 2002, 100 (11) : 357A - 358A
  • [10] Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) following treatment for ovarian cancer
    Gupta, B.
    Sait, S. N.
    Block, A. W.
    Ford, L. A.
    Moysich, K. B.
    Baer, M. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345